Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613145 · ClinicalTrials.gov registry record · Phase 1
Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00613145 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 32 participants.
The verdict
NCT00613145, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a phase I, randomized, safety and pharmacokinetic (PK) study of sorafenib given in combination with capecitabine. The study will enroll two simultaneous cohorts; patients will be randomly assigned to either Cohort A or Cohort B. A third cohort (C) may be added to the protocol at a later date.
Interventions
- DRUG Capecitabine and Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00613145
The ClinicalTrials.gov registry entry for NCT00613145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Capecitabine and Sorafenib is the first listed.
NCT00613145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00613145 about?
NCT00613145 is a clinical study titled "Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors". This is a phase I, randomized, safety and pharmacokinetic (PK) study of sorafenib given in combination with capecitabine. The study will enroll two simultaneous cohorts; patients will be randomly assigned to either Cohort A or Cohort B. A third cohort (C) may be added to the protocol at a later date...
What is the current status of trial NCT00613145?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2008-02. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00613145?
The interventions under investigation include: Capecitabine and Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00613145?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.